Biotech analyst Brian Skorney and biotech executive Daphne Zohar discuss the potential impact of a new Trump administration on the FDA, biotech industry, and stocks on “The Readout LOUD.” The conversation covers key points about the future direction of regulations and policies under a new administration. Listeners can access the full episode for more details. The discussion was edited for length and clarity. Subscribers can access exclusive content and daily coverage of the biotech sector through STAT+. The conversation provides valuable insights into how political changes may affect the biotech landscape.
Source link
Biotech analyst Brian Skorney and CEO Daphne Zohar on Trump’s reelection
